Quinoxalinone–benzimidazole rearrangement: an efficient strategy for the synthesis of structurally diverse quinoline derivatives with benzimidazole moieties
作者:Vakhid A. Mamedov、Venera R. Galimullina、Nataliya A. Zhukova、Saniya F. Kadyrova、Ekaterina V. Mironova、Il’dar Kh. Rizvanov、Shamil K. Latypov
DOI:10.1016/j.tetlet.2014.06.023
日期:2014.7
A novel and efficient procedure for the synthesis of structurallydiverse benzimidazolylquinolines has been realized through a new acid-catalyzed quinoxalinone–benzimidazole rearrangement of the spiro-quinoxalinone derivatives formed in situ from the reaction of 3-(2-aminophenyl)quinoxalin-2(1Н)-ones and different ketones.
通过3-(2-氨基苯基)喹喔啉2(1 Н)-一个和不同的酮。
Friedländer reaction/quinoxalinone–benzimidazole rearrangement sequence: expeditious entry to diverse quinoline derivatives with the benzimidazole moieties
作者:Vakhid A. Mamedov、Saniya F. Kadyrova、Nataliya A. Zhukova、Venera R. Galimullina、Fedor M. Polyancev、Shamil K. Latypov
DOI:10.1016/j.tet.2014.06.007
日期:2014.9
3-(2-aminophenyl)quinoxalin-2(1H)-ones and ketones, including acetone, acetophenones, 1,3-pentanedione and ethyl acetoacetate. The selective formation of the very different quinoline derivatives depends on the structure of ketones. The key steps are proposed to involve the new acid-catalyzed rearrangement of the spiro-quinoxalinone derivatives formed in situ from the reaction of 3-(2-aminophenyl)quinoxalin-2(1H)-ones
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.